4DMedical Ltd ( (AU:4DX) ) has shared an update.
4DMedical Limited has secured two new contracts to supply its advanced lung imaging technology for clinical trials, one with SMS Biotech for a COPD stem cell therapy trial and another with an unnamed medical device developer. This highlights 4DMedical’s growing role in the respiratory health sector and its strategic partnerships aimed at advancing lung disease treatments. Additionally, 4DMedical’s technology was featured in a US Congressional testimony by Philips, emphasizing its potential to improve veteran healthcare outcomes through enhanced pulmonary diagnostics.
More about 4DMedical Ltd
4DMedical Limited is a company specializing in respiratory imaging technology. It provides innovative software tools for analyzing lung structure and function, with a focus on supporting the development of new therapies for lung diseases. The company is engaged in collaborations with pharmaceutical and device companies to enhance respiratory care and streamline clinical trials.
YTD Price Performance: -45.83%
Average Trading Volume: 1,004,852
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$112.6M
Find detailed analytics on 4DX stock on TipRanks’ Stock Analysis page.